Taro Kishi Kenji Sakuma Masakazu Hatano Takenori Okumura Masaki Kato Hajime Baba Nakao Iwata
Neuropsychopharmacology reports 2024年2月
AIM: To update the major depressive disorder (MDD) treatment guidelines of the Japanese Society of Mood Disorders, we conducted a systematic review and pairwise meta-analysis of double-blind, randomized, placebo-controlled trials of available anti...
Yupeng He Masaaki Matsunaga Yuanying Li Taro Kishi Shinichi Tanihara Nakao Iwata Takahiro Tabuchi Atsuhiko Ota
JMIR Formative Research 7 e50193-e50193 2023年11月
Background
In Japan, challenges were reported in accurately estimating the prevalence of schizophrenia among the general population. Retrieving previous studies, we investigated that patients with schizophrenia were more likely to experience poo...
Journal of psychiatric research 167 132-138 2023年10月
The benefits of serotonin 3 receptor antagonists (5-HT3R-As) in obsessive-compulsive disorder (OCD) treatment remain unclear. Thus, this study aimed to perform a systematic review and a random-effects meta-analysis, including double-blind, randomi...
Taro Kishi Kenji Sakuma Masakazu Hatano Yuki Matsuda Satoru Esumi Nobumi Miyake Itaru Miura Hikaru Hori Masaki Kato Nakao Iwata
Neuropsychopharmacology reports 2023年8月
INTRODUCTION: The question remains to be elucidated: "Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?" It is crucial to confirm this in order to provide appropriate treatments for Japanese pat...
Neuropsychiatric disease and treatment 15 2425-2432 2019年 [査読有り]
Objective: Recently, a genome-wide association study successfully identified genetic variants associated with major depressive disorder (MDD). The study identified 17 independent single-nucleotide polymorphisms (SNPs) significantly associated with...
お知らせ・マニュアル
医学部